Drug-Related side effects of long-term intrathecal morphine therapy

Pain Physician

Volumn 10, Issue 2, 2007, Pages 357-365

  Ruan, Xiulu ^a  

^a Physician's Pain Specialists of Alabama   (United States)

Author keywords

Intrathecal morphine; Opioid receptors; Side effects

Indexed keywords

ANTIHISTAMINIC AGENT; BETHANECHOL; CLONIDINE; DOCUSATE SODIUM; DOMPERIDONE; DROPERIDOL; FENTANYL; HALOPERIDOL; HYDROMORPHONE; HYDROXYZINE; KETAMINE; LAXATIVE; LIDOCAINE; LORAZEPAM; MECLOZINE; METHADONE; METHYLPHENIDATE; METOCLOPRAMIDE; MODAFINIL; MORPHINE; NALBUPHINE; NALOXONE; ONDANSETRON; OPIATE; OPIATE RECEPTOR; OXYMORPHONE; PROCHLORPERAZINE; PROMETHAZINE; SCOPOLAMINE; UNINDEXED DRUG;

ANXIETY; BIBLIOGRAPHIC DATABASE; BRADYPNEA; CANCER PAIN; CATATONIA; CATHETER COMPLICATION; CENTRAL NERVOUS SYSTEM DEPRESSION; CHRONIC PAIN; CLINICAL TRIAL; COMA; COMPRESSION THERAPY; CONSTIPATION; DELIRIUM; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG TOLERABILITY; DRUG UPTAKE; DRUG UTILIZATION; EDEMA; EUPHORIA; EVIDENCE BASED MEDICINE; FLUID RETENTION; FOOT EDEMA; GASTROINTESTINAL MOTILITY; GRANULOMA; HALLUCINATION; HUMAN; HYDROPHILICITY; HYPERALGESIA; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; IMPOTENCE; INFUSION PUMP; INTRACTABLE PAIN; LEG EDEMA; LETHARGY; LIBIDO DISORDER; LONG TERM CARE; LOW DRUG DOSE; MEDICAL LITERATURE; MENTAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PARANOID PSYCHOSIS; PATHOGENESIS; PATIENT COUNSELING; PERIPHERAL EDEMA; PRURITUS; RECURRENT DISEASE; RESPIRATION DEPRESSION; RESPIRATORY ACIDOSIS; RESPIRATORY FAILURE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; URINE RETENTION; VOMITING; VULNERABLE POPULATION;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, SPINAL; MORPHINE; NAUSEA; PAIN, INTRACTABLE; PRURITUS; URINARY RETENTION; VOMITING;

EID: 34147165134     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Goldstein A, Lowney, LI, Pal, BK. Stereospecific and nonspecific interactions of the morphine congener levorphanol in the subcelluar fractions of mouse brain. Proc Natl Acad Sci USA 1971;68:1742-1747.
2. Pert CB, Snyder, SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011-1014.
3. Lamotte C, Pert CB, Synder SH. Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section. Brain Res 1976;12:407-412.
4. Yaksh TL, Rudy TA. Analgesia mediated by a direct spinal action of narcotics. Science 1976; 192:1357-1358.
5. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology. 1979; 50:149-151.
6. Krames, E. Intraspinal Analgesia for nonmalignant pain, Interventional Pain Management, 2nd Edition, 2001 60; 609-619.
7. Raphael JH, Southall JL, Gnanadurai TV, Trehame GI, Kitas GD; Long-term Experience with implanted intrathecal drug administration systems for failed back syndrome and mechanical low back pain, BMC Musculoskeletal Disord 2002; 3: 17.
8. Deer T, Chapple I, Classen A, Javery D, Stoker, V, Tonder, Burchiel K. Intrathecal drug delivery for treatment of chronic low back pain: Report from the National Outcomes Registry for Low Back Pain. Pain Med 2004; 5:6-13.
9. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001; 55:79-88.
10. Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmaligmant pain. Congress of Neurological Surgeons Vol 44(2), Feb. 1999, pp289-300.
11. Holtsman M, Fishman SM. Opioid receptors. In Benton HT, Raja N, Molloy, RE, Liu S, Fishman SM. Essentials of Pain Medicine and Regional Anesthesia. 2nd Edition. 2005 Chapter 10:87-91.
12. Winkelmuller, M, Winkelmuller, W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of non-malignant etiology. J Neurosurg 1996;85:458-467.
13. Chaney, MA. Side effects of intrathecal and epidural opioids. Can J Anaesth 1995; 42:891-903.
14. Chauvin M, Samii K, Schermann JM, Sandour P, Bourdon R, Viars P. Plasma pharmacokinetics of morphine after I.M., extradural and intrathecal administration. Br J Anaesth 1982; 54:843-847.
15. Hansdottir V, Hedner T, Woestenborghs R, Nordberg G. The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. Anesthesiology 1991; 74:264-269.
16. Ionescu, TI, Taverne RH, Houweling PL, Drost RH, Nuijten S, Van Rossum J. Pharmacokinetic study of extradural and intrathecal sufentanil anaesthesia for major surgery. Br J Anaesth 1991;66:458-464.
17. Di Chiro G. Observations on the circulation of the CSF. Acta Radial 1996;5:988-1002.
18. Johnson A, Bengtsson M, Lofstrom JB, Rane A, Wahlstrom A. Influence of post-operative naloxone infusion on respiration and pain relief after intrathecal morphine. Reg Anesth 1988; 13:146-151.
19. Gowan JD. Naloxone infusion after prophylactic epidural morphine: effects on incidence of postoperative side-effects and quality of analgesia. Can J Anaesth 1988;35:143-148.
20. Cousins MJ, Mather, LE. Intrathecal and epidural administration of opioids. Anesthesiology 1984;61:276-310.
21. Morgan M. The rational use of intrathecal and extradural opioids. Br J Anaesthe 1989;63:165-188.
22. Bailey PL, Rhondeau S, Schafer PG, Lu JK, Timmons, BS. Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology 1993;79:49-59.
23. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988;33:149-160.
24. Hu JW, Dostrovsky JO, Sessle BJ. Functional properties of neurons in cat triageminal subnucleus caudalis (medullary dorsal horn). I. Response to oral-facial noxious and non-noxious stimuli and projections to thalamus and subnucleus oralis. J Neurophysiol 1981;45:173-192.
25. Scott PV, Fischer HBJ. Intraspinal opiates and itching: a new reflex? BMJ 1982; 284:1015-1016.
26. Raj PR. Practical Management of Pain. 3rd Edition. 2000 Common analgesic side effects and treatment. Appendix D. 1025-1026.
27. Yeh HM, Chen LK, Lin CJ, Chan WH, Chen YP, Lin CS. Prophylactic intravenous ondansetron reduces the incidence of intrathecal morphine induced pruritus in patients undergoing cesarean delivery. Anesth Analg 2000.91:172-175.
28. Yazigi A. Prophylactic ondansetron is effective in the treatment of nausea and vomiting but not on pruritus after cesarean delivery with intrathecal sufentanil-morphine. J Clin Anesth 2002. 14:183-186.
29. Charuluxananan S, Kyokong O, Somboonviboon W, Lertmaharit S, Ngampraserwong P, Nimcharoendee K. Nalbuphine versus propofol for treatment of intrathecal morphine-induced pruritus after cesarean delivery. Anesth Analg 2001. 93:162-165.
30. Charuluxananans KO, Somboonviboon W, Narasethakomol A, Promlok P. Nalbuphine versus ondansetron for prevention of intrathecal morphine-induced pruritus after cesarean delivery. Anesth Analg 2003. 96:1789-1793.
31. Raffaeli W, Marconi G, Fanelii G, Taddei S, Borghi GB, Casati A. Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose-response study. Eur J Anaesth 2006; 23:605-610.
32. Synder SH. Opiate receptors in the brain. N Eng J Med 1977;296:266-71.
33. Wang SC, Borison HL. The vomiting center. Archives of neurology and psychiatry 1950;63:928-41.
34. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, Makriyannis A, Malan PT. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 2001. 94:882-887.
35. Loper KA, Ready LB, Dorman BH. Prophylactic transdermal scopolamine patches reduce nausea in postoperative patients receiving epidural morphine. Anesth Analg 1989; 68:144-146.
36. Wattwil, M. Postoperative pain relief and gastrointestinal mobility. Acta Chir Scand 1988;550:140-5.
37. Frederich, ME. Nonpain symptom management. Prim Care 2001; 28:299-316.
38. Peterson TK, Husted SE, Rybro L, Schurizek BA, Wernberg, M. Urinary retention during I.M. and extradural morphine analgesia. Br J Anesth 1982;54:1175-1178.
39. Morgan, M. The rational use of intrathecal and extradural opioids. Br J Anaesth 1989;63:165-188.
40. Rawal N, Mollefors K, Axelsson K, Lingardh G, Wldman B. An experimental study of urodynamic effects of epidural morphine and naloxone reversal. Anesth Analg 1983; 62:641-647
41. Durant PAC, Yaksh TI. Drug effects on urinary bladder tone during spinal morphine-induced inhibition of the micturition reflex in un-anesthesitized rats. Anesthesiology 1988.68:325.
42. Patt RB, Hassenbusch SJ. Implantable technology for pain control: identification and management of problems and complications. Interventional Pain Management by Steven Waltman 2nd Edition. 2001 Chapter 64:663.
43. Drenger B, Magora F, Evron S, Caine M. The action of intrathecal morphine and methadone on the lower urinary tract in the dog. J Urol 1986; 135:852-855.
44. Wang J, Pennefather S, Russell G. Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia. Br J Anaesth 80:565-566.
45. Practice guidelines for cancer pain management: A report by the American Society Task Force on Pain Management, Cancer Pain Section. Anesthesiology 1996.84:1243-1257.
46. Yaksh TL, Noveihed R. The physiology and pharmacology of spinal opiates. Ann Rev Pharmacol Toxicol 1985;25:433-62.
47. Porreca F, Filia A, Burks TF. Spinal cord mediated opiate effects on gastrointestinal transit in mice. Eur J Pharmacol 1983;86:135-136.
48. Thoren T, Wattwil M. Effects on gastric emptying of thoracic epidural analgesia with morphine or bupivacaine. Anesth Analg 1988;67:687-694.
49. Harris JD, Kotob F. Management of opioid-related side effects. In De Leon-Casasola OA, Cancer Pain. Saunders, 2006. Chapter 18:212-230.
50. Mahajan G, Fishman SM. Opioid therapy: adverse effects including addiction. Essentials of Pain Medicine and Regional Anesthesia. 2nd Edition. 2005 Chapter 13:113-123.
51. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002; 23:48-53.
52. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: a restrospective study. Pain Medicine Vol 2, No 4, 2001:287-97.
53. Aldrete JA, Couto da Silva JM. Leg edema from intrathecal opiate infusions. Eur J Pain 2000; 4:361-365.
54. Paice JA, Penn R, Shott S. Intraspinal morphine for chronic pain: A retrospective multicenter study. J Pain Symptom Manage 1996; 11:71-80.
55. Sidi A, Davidson JT, Behar M, Olshwang D. Spinal narcotics and central nervous system depression. Anaesthesia 1981;36:1044-1047.
56. Paulus DA, Paul W, Munson ES. Neurological depression after intrathecal morphine. Anesthesiology 1981;54:517-518.
57. Christie JM, Meade WR, Markowsky S. Paranoid psychosis after intrathecal morphine. Anesth Analg 1993;77:1298-1299.
58. Rawal N, Arnér, S, Gustafsson LL, Allvin, R. Present state of extradural and intrathecal opioid analgesia in Sweden. Br. J Anaesth 1987;59:791-799.
59. Bruera E, Miller MJ, Macmillan K, Kuehn N. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992.48:163-66.
60. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Medicine 2003; 4:135-140.
61. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, Verlooy J, Van Havenbergh T, Smet M, Van Acker K. Endocrine Consequences of long-term intrathecal administration of opioids. J of Clinic Endocrininology & Metablism 2000 Vol. 85, No. 6:2215-2222.
62. Katz N. The impact of opioids on the endocrine system. 2005. Pain Management Rounds 1.
63. Gustafsson LL, Schildet B, Jacobsen K. Adverse effects of extradural and intrathecal opiates: report of a nationwide survey in Sweden. Br. J. Anaesth 1982;54:479-486.
64. Scherens A, Kagel T, Zenz M, Maier C. Long-term respiratory depression induced by intrathecal morphine treatment for chronic neuropathic pain. Anesthediology 2006;105:431-433.
65. Holtsman M, Fishman SM. Opioid Receptors. Chapter 10. Essentials of Pain Medicine and Regional Anesthesia. 2005 2nd Edition.
66. Shook JE, Watkins WD, Camporesi EM. Differential roles of opioid receptors in respiration, respiratory disease, and opioid-induced respiratory depression. Am Rev Respir Dis 1990; 142:895-909.
67. Baise GA, McMichan JC, Nugent M, Hollier LH. Nalbuphine produces side effects while reversing narcotic induced respiratory depression. Anesth Analg 1986; 65(Suppl):S19.
68. Hammond JE. Reversal of opioid associated late onset respiratory depression by nalbuphine hydrochrloride. Lancet. 1984; 2:1208.
69. Schmauss C, Doherty C, Yaksh TL. The analgesic effects of an intrathecally administered partial opiate agonist, nalbuphine hydrochloride. Eur J Pharmacol 1983; 86:1.
70. Kaiser KG, Bainton CR. Treatment of intrathecal morphine overdose by aspiration of cerebrospinal fluid. Anesth Analg 1987; 66:475.
71. Yaksh TL, Harty GJ, Onofrio BM. High doses of spinal morphine produces a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implication. Anesthesiology 1986; 64:590-597.
72. Dunbar SA, Karamian IG. Periodic abstinence enhances nociception without significantly altering the antinociceptive efficacy of spinal morphine in the rat. Neurosci Lett 2003; 344:145-148.
73. Johnston IN. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004; 24:7353-7365.
74. Mao J. Chronic morphine induces downregulation of spinal glutamate transporters: Implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002; 22:8312-8323.
75. Vanderah TW. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000; 20:7074-7079.
76. Ali NMK. Hyperalgesic response in a patient receiving high concentration of spinal morphine(Letter). Anesthesiology 1986; 65:449.
77. Wilson GR, Reisfield, GM. Morphine hyperalgesia: A case report. Am J Hosp Palliat Care 2003; 20:459-461.
78. De Canna F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47:337-339.
79. Parisod E. Allodynia after acute intrathecal morphine administration in a patient with neuropathic pain after spinal cord injury. Anesth Analg 2003; 97:183-186.
80. Angst MS, Clark JD. Opioid induced hyperalgesia: A Qualitative systematic review. Anesthesiology 2006; 104:570-587.
81. Sakurada T, Komatsu T, Sakurada S. Mechanisms of nociception evoked by intrathecal high-dose morphine. NeuroToxicology 2005; 26: 801-809.
82. Woolf CJ. Intrathecal high hose morphine produces hyperalgesia in the rat. Brain Res 1981; 209:491-495.
83. Yaksh TL, Harty GL. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. J Pharmcol Exp Ther 1988; 244:501-507.
84. Man J, Price DD, Mayer DJ. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994; 14:2301-2312.
85. Dunbar SA, Pulai IJ. Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat. J Pharmacol Exp Ther 1998; 284:678-686.
86. Ibuki T, Marsala M, Masuyama T, Yaksh TL. Spinal amino acid release and repeated withdrawal in spinal morphine tolerant rats. Br J Pharmacol 2003; 138:689-697.
87. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999; 289:1048-1053.
88. Inturrisi CE. Pharmacology of methadone and its isomers. Minerva Anestesiol 2005; 71:435-437.
89. Bell RF, Eccleston C, Kalso E. Ketamine as adjuvant to opioid for cancer pain: A qualitative systematic review. J Pain Symptom Manage 2003; 26:867-875.
90. De Kock M, Lavand'homme P, Waterloos H. "Balanced analgesia": in the perioperative period: is there a place for Ketamine? Pain 2001; 92:373-380.
91. Quan DB, Wandres DL, Schroeder DJ. Clonidine in pain management. Ann Pharmacother 1993; 27:313-315.
92. Ferrini R, Paice JA. How to initiate and monitor infusional lidocaine for severe and/or neuropathic pain. J Support Oncol 200/4; 2:90-94.
93. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/ dependence during chronic cotreatment. Proc Natl Acad Sci USA 1995; 92:1540-1544.
94. Crain SM, Shen KF. Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent analgesia. Brain Res 2001; 888:75-82.
95. Mercadante S, Villari P, Ferrera P. Naloxone in treating central adverse effects during opioid titration for cancer pain. J Pain Symptom Manage. 2003; 26:691-693.
96. North RB, Cutchis RN, Epstein JA, Mong DM. Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery 1991; 29:778-784.
97. Schuchard M, Lanning R, North R, Reig R, Krames E. Neurological sequelae of intraspinal drug delivery systems. Neuromodulation 1998; 1:137-148.
98. Langsam, A. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: Case report. Neurosurgery 1999; 44:689-691.
99. Cabbell KL, Taren JA, Sagher O. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery 1998; 42:1176-1180.
100. Blount JP, Remley KB, Yue SK, Erickson DL. Intrathecal granuloma complicating chronic spinal infusion of morphine: report of three cases. J Neurosurg 1996; 84:272-276.
101. Bejjani GK, Karim NO, Tzortzidis F. Intrathecal granuloma after implantation of a morphine pump: case report and review of the literatures. Surg Neurol 1997; 48:288-291.
102. Aldrete JA, Vascello LA, Ghaly R, Tomlin D. Paraplegia in a patient with an intrathecal catheter and a spinal cord stimulator. Anesthesiology 1994; 81:1542-1545.
103. Toombs JD, Follett KA, Rosenquist RW, Benton LM. Intrathecal catheter tip inflammatory mass: a failure of Clonidine to protect. Anesthesiology 2005; 102:687-690.
104. Coffey, RJ, Burchiel, K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: report and observations on 41 patients. Neurosurgery 2002; 50:78-87.
105. Yaksh T, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med 2002; 3: 300-312.
106. Hassenbusch S, Burchiel K, Coffey RJ, Cousins MJ, Deer T, Hahn MB, Du Pen S, Follett KA, Krames E, Rogers JN, Sagher O, Staats PA, Wallace M, Willis KD (2002). Management of intrathecal catheter-tip inflammatory masses: A consensus statement. Pain Med 2002;3:313-323.
107. Allen JW, Horais KA, Tozier NA, Wegner K, Corbeil JA, Mattrey RF, Rossi SS, Yaksh TL. Time course and role of morphine dose and concentration in intrathecal granuloma formation in dogs. Anesthesiology 2006; 105:508-509.
108. Follett, KA. Intrathecal opioid infusion. Anesthesiology 2004; 101:256.
109. Yaksh, TL, Horais KA, Tozier NA, Allen JW, Rathbun M, Rossi SS, Sommer C, Meschter C, Richter PJ, Hildebrand KR. Chronically infused intrathecal morphine in dogs. Anesthesiology 2003; 99:174-197.
110. Allen, JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006; 105:590-598.
111. Peng P, Massucitte EM. Spinal cord compression from intrathecal catheter-tip inflammatory mass: Case report and a review of etiology. Reg Anesth Pain Med 2004: 29:237-242.
112. McMillan, MR. Intrathecal morphine and inflammatory masses. Anesthesiology 2004; 101:255.
113. Coffey, RJ, Burchiel, K. Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients. Neurosurgery 2002; 50: 78-87.